





<b>AMENDMENT TRANSMITTAL LETTER (Large Entity)</b>				Docket No. 01139/3/US	
Applicant(s): Allenspach et al.					
Application No. 10/647,501	Filing Date August 25, 2003	Examiner Gregory W. Mitchell	Customer No. 26648	Group Art Unit 1614	Confirmation No. 2375
<div style="display: flex; justify-content: space-between;"> <div style="text-align: center;">  </div> <div> <p><b>PHARMACEUTICAL COMPOSITION EXHIBITING CONSISTENT DRUG RELEASE PROFILE</b></p> </div> </div>					
<b>COMMISSIONER FOR PATENTS:</b>					
Transmitted herewith is an amendment in the above-identified application.					
The fee has been calculated and is transmitted as shown below.					
<b>CLAIMS AS AMENDED</b>					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	29 -	29 =	0	x \$50.00	\$0.00
INDEP. CLAIMS	4 -	4 =	0	x \$200.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>					<b>\$0.00</b>
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account <b>19-1025</b> <input type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038.					
<b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b>					
 _____ <i>Signature</i>			Dated: <b>March 9, 2005</b>		
Patricia K. Fitzsimmons, Reg. No. 52,894 Pharmacia Corporation of Pfizer Inc. P.O. Box 1027 Chesterfield, Missouri 63006 314.274.1490			I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on <div style="text-align: center;">             March 9, 2005              (Date)           </div> <div style="text-align: center;">   <i>Signature of Person Mailing Correspondence</i> </div> <div style="text-align: center;"> <b>Linda K. Cooper</b>  <i>Typed or Printed Name of Person Mailing Correspondence</i> </div>		
cc:					



**TRANSMITTAL LETTER**  
**(General - Patent Pending)**

Docket No.  
01139/3/US

Re Application Of: Allenspach et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/647,501	August 25, 2003	Gregory W. Mitchell	26648	1614	2375

Title: **PHARMACEUTICAL COMPOSITION EXHIBITING CONSISTENT DRUG RELEASE PROFILE**

COMMISSIONER FOR PATENTS:

Transmitted herewith is:

**Amendment Transmittal; Amendment A; Itemized Postcard.**

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **19-1025** as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

*Patricia K. Fitzsimmons*  
\_\_\_\_\_  
Signature

Dated: **March 9, 2005**

Patricia K. Fitzsimmons, Reg. No. 52,894  
Pharmacia Corporation of Pfizer Inc.  
P.O. Box 1027  
Chesterfield, Missouri 63006  
314.274.1490

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

March 9, 2005

(Date)

*Linda K. Cooper*  
\_\_\_\_\_  
Signature of Person Mailing Correspondence

**Linda K. Cooper**

Typed or Printed Name of Person Mailing Correspondence

cc:



1FW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Allenspach et al. ) GROUP ART UNIT: 1614  
SERIAL NO.: 10/647,501 ) CONFIRMATION NO.: 2375  
EXAMINER: Mitchell, Gregory W. ) ATTORNEY DOCKET NO.: 01139/3/US  
FILED: August 25, 2003 )  
TITLE: PHARMACEUTICAL COMPOSITION EXHIBITING CONSISTENT  
DRUG RELEASE PROFILE

CERTIFICATE OF MAILING

I hereby certify that this communication and any recited enclosures are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on **March 9, 2005**.

  
Linda K. Cooper

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

March 9, 2005

**AMENDMENT A**

Sir:

Please amend the above-identified application as follows:

**Amendments to the Specification** begin at page 2 of this paper.

**Remarks/Arguments** begin on page 3 of this paper.